$195.14
+167.61 (+608.83%)
1Y
About
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline enco...
HQ: Cambridge, MA · Founded: 2010 · Employees: 4,700 · CEO: Stéphane Bancel ·Revenue (TTM): $1.9B
www.modernatx.com Company Info
Sector
Health Care Industry
Biotechnology Country
United States Exchange
NASDAQ Currency
USD Financial Metrics
Day Range
$192.71 $199.92
52-Week Range
$22.28 $212.22
Prev Close
$196.48 Market Cap
$74.4B P/E Ratio
-23.5 Forward P/E
23.0 EPS (TTM)
$-7.26 Profit Margin
-141.4% Div Yield
— Annual Dividend
— Avg Volume
15M Beta
0.89 Track MRNA in your portfolio
See how Moderna, Inc. affects your portfolio risk, drawdown, and diversification.
Get started